KDM1A and small cell lung carcinoma: A phase 1/2 study of the selective inhibitor of LSD1, iadaemstat, plus PD-1 inhibitors as maintenance therapy in SCLC who complete induction chemoimmunotherapy is supported by the NCI-CTEP and will be opened.